By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genentech 

1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


SEARCH JOBS
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:
http://www.youtube.com/genentech#p/u/1/GJH4X5gxxf0

Connect with us via Social Media:

Facebook: www.facebook.com/GenentechJobs

Twitter: www.twitter.com/GenentechJobs

LinkedIn: www.linkedin.com/company/genentech


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY
 



Industry
Biotechnology

Segment
Biotherapeutics





Company News
In A Pivotal Study, Genentech (RHHBY)’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Bladder Cancer 7/13/2015 6:19:34 AM
Genentech (RHHBY)’s Breakthrough Atezolizumab Joins Club of Successful Anti-PD-L1 Drugs, Shrinks Tumors in Bladder Cancer 7/13/2015 6:18:41 AM
Exelixis (EXEL) Provides Update On Genentech (RHHBY)’s Pending New Drug Application For Cobimetinib, An Exelixis-Discovered Compound 7/1/2015 9:09:44 AM
The Power of Being a Genentech (RHHBY) Alumni 7/1/2015 6:31:20 AM
Genentech (RHHBY)’s Ocrelizumab Significantly Reduced Both Relapses And Disability Progression Versus Interferon Beta-1a (Rebif) In Two Phase III Studies In Multiple Sclerosis 6/30/2015 6:11:12 AM
Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market 6/30/2015 6:10:01 AM
Dream Foundation Announces Troy Cox, Genentech (RHHBY) Senior Vice President And Officer, Has Been Appointed To The Board Of Directors 6/17/2015 8:57:25 AM
Almac Discovery Wrangles R&D Deal Worth $363.5 Million+ From Genentech (RHHBY) 6/15/2015 6:31:19 AM
EXCLUSIVE: Genentech (RHHBY) Enrolling Patients in Phase III Actemra Trial, Company Tells BioSpace (DHX) 6/10/2015 12:25:59 PM
Genentech (RHHBY) Wins Breakthrough Nod From FDA for Systemic Sclerosis Treatment 6/10/2015 6:14:25 AM
12345678910...
//-->